| News

CEO of Novartis pinning hopes on malaria drug

30.03.2020

In the fight against the coronavirus, Vas Narasimhan, CEO of Novartis, is above all pinning his hopes on a malaria drug. Narasimhan has claimed in an interview that this drug has proven in preclinical and initial clinical trials that it can destroy the virus. At the moment, patients are being enrolled for studies.

Vas Narasimhan, CEO of Novartis (img: Novartis)

In the opinion of Vas Narasimhan, the first wave of the coronavirus pandemic may have reached its peak in Spain and Italy, but will spread further in the USA. Now it is time to prepare for the next wave. The CEO of Basel-based Novartis is above all pinning his hopes on hydroxychloroquin, a drug used to treat malaria, which the company are focusing their work on.

“Preclinical trials in animals as well as initial data from clinical trials have shown that it destroys the coronavirus”, Narasimhan states in an interview with SonntagsZeitung. “We are working together with Swiss hospitals to check potential treatment protocols for clinical application, but it’s too early to offer anything definitive in this regard yet”, he adds. At the moment, the first patients are being recruited for enrolment in studies. Moreover, Novartis is in dialog with the regulatory authorities in Switzerland and the USA in order to obtain authorization by way of summary proceedings.

Novartis has at its disposal the raw material for 130 million doses. Export bans in India could, however, be an obstacle to production, Narasimhan explains. “Our plant in Stein AG would be the worst hit by export bans, as it currently procures raw materials on a global basis”. The pharma industry is reliant on the free flow of goods, with no country fully self-sufficient in this regard.

Together with 15 pharmaceutical firms from around the world in total, Novartis has committed its expertise to the Bill & Melinda Gates Foundation in the fight against the coronavirus pandemic. To this end, the group of pharma firms are to open up their proprietary libraries of molecular compounds to in the joint search for candidates to combat the virus.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Novartis Campus
Basel Area Business & Innovation, Switzerland Innovation Park

Switzerland Innovation Park Basel Area Site Novartis Campus

We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.

Read More
Basel Area Business & Innovation, Switzerland Innovation Park

The innovation and enterprise campus GRID is filling up

Two institutes from the University of Basel and a pharmaceutical company are relocating to the GRID innovation and enterprise campus, which is currently under construction at BaseLink in Allschwil. The new building will also contain the headquarters of the Switzerland Innovation Park Basel Area in future.

Read More
Basel Area Business & Innovation, Innovation

Artidis ends successful study

Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.

Read More
Basel Area Business & Innovation, Innovation

Startup Academy celebrates anniversary

Startup Academy is on the road to success ten years after being founded. The initiative has supported 280 startups to date. The project was originally started in Basel and is now represented at several locations in Switzerland with plans for further growth.

Read More
Basel Area Business & Innovation, Invest

Syngenta grows strongly and stays true to Basel

Syngenta AG, Adama and Sinochem are to be united under the umbrella of the new Syngenta Group. The group is headquartered in Basel and employs around 48,000 staff across over 100 countries.

Read More
Basel Area Business & Innovation, Innovation

Tolremo raises additional funding

The Muttenz-based biotechnology company Tolremo Therapeutics has raised an additional 4.7 million Swiss francs as part of a financing round. The company develops cancer therapies for precision medicine and is now driving forward clinical development.

Read More
Ruben Herrendorff, CEO Polyneuron Pharmaceuticals
Basel Area Business & Innovation, Innovation

Polyneuron medication receives orphan drug status in the USA

The American health authority has granted Polyneuron’s drug PN-1007 orphan designation. This status uses special conditions to balance out commercial disadvantages when developing drugs for rare diseases.

Read More
Basel Area Business & Innovation, Innovation

BaseLaunch Applications open

BaseLaunch helps build therapeutic ventures to the point where they can raise a Series-A financing round or similar.

Read More
Basel Area Business & Innovation, Innovation

i4Challenge Applications open

The i4Challenge is an acceleration program for SME, startups and new projects focused on innovative solutions, new approaches and next-generation products or services for Industry 4.0.

Read More
Basel Area Business & Innovation, Invest

Ricola earns the trust of Switzerland

Ricola has been voted the most trustworthy brand in Switzerland. The manufacturer of herbal candy, which is based in the Basel Area, previously won this award in 2017.

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.